WallStSmart

Insmed Inc (INSM)vsProthena Corporation plc (PRTA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 6162% more annual revenue ($606.42M vs $9.68M). PRTA leads profitability with a 0.0% profit margin vs -2.1%. PRTA appears more attractively valued with a PEG of 0.80. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

PRTA

Hold

38

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 6.7Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

PRTA2 strengths · Avg: 8.0/10
PEG RatioValuation
0.808/10

Growing faster than its price suggests

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

PRTA4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$474.81M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-63.6%2/10

ROE of -63.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : PRTA

The strongest argument for PRTA centers on PEG Ratio, Price/Book. PEG of 0.80 suggests the stock is reasonably priced for its growth.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : PRTA

The primary concerns for PRTA are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while PRTA is a value play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

PRTA generates stronger free cash flow (-27M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 38/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Prothena Corporation plc

HEALTHCARE · BIOTECHNOLOGY · USA

Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The company is headquartered in Dublin, Ireland.

Want to dig deeper into these stocks?